Last updated: February 23, 2026
What is the drug designated by NDC 42291-0455?
The National Drug Code (NDC) 42291-0455 corresponds to Tucatinib (Cyramza), an oral tyrosine kinase inhibitor targeting HER2-positive metastatic breast cancer. Approved by the FDA in April 2020, it is marketed by Seattle Genetics, in collaboration with Amgen. The drug is used in combination with trastuzumab and capecitabine for treating adult patients with unresectable or metastatic HER2-positive breast cancer.
Market Landscape for HER2-Positive Metastatic Breast Cancer Treatments
Current Market Size and Growth
| Metric |
Data |
Year |
Notes |
| Global HER2-positive breast cancer market |
USD 4.8 billion |
2022 |
Estimated, driven by rising incidence and expanded indications |
| CAGR (Compound Annual Growth Rate) |
approx. 8.2% |
2022-2027 |
Growth driven by new targeted therapies and improved diagnostics |
| U.S. breast cancer prevalence |
268,600 cases annually |
2022 |
Approximate for new diagnoses; HER2-positive cases constitute ~15-20% |
Competitive Landscape
| Drug |
Mechanism |
Approval Date |
Market Share |
Pricing Model |
| Trastuzumab |
Monoclonal antibody targeting HER2 |
1998 |
Dominant |
Per-dose, ~$3,000 |
| Pertuzumab |
Monoclonal antibody, HER2 dimerization inhibitor |
2012 |
Significant |
Per-dose, ~$4,000 |
| T-DM1 (trastuzumab emtansine) |
Antibody-drug conjugate |
2013 |
Growing |
Per-dose, ~$5,000 |
| Tucatinib (42291-0455) |
Tyrosine kinase inhibitor |
2020 |
Niche, expanding |
Per-month, ~$9,500 |
Adoption and Usage Trends
- Tucatinib's approval was based on the HER2CLIMB trial showing improvements in progression-free survival and overall survival.
- It is used primarily in patients with brain metastases, a population with limited options.
- Market penetration remains limited but is expanding as clinicians incorporate it into treatment sequences.
Price Projections and Economic Considerations
Current Pricing
| Price Metric |
Data |
Notes |
| Wholesale Acquisition Cost (WAC) per month |
~$9,500 |
Standard pricing, varies by payer and region |
| List price per 28-day cycle |
~$9,500 |
Corresponds to a typical dosing schedule |
| Patient out-of-pocket costs |
Varies |
Typically high without insurance; biosimilars may affect pricing dynamics |
Short-term (2023-2025) Projections
- Price reduction pressures, driven by increased biosimilar entry for competing HER2 therapies.
- Payers push for value-based arrangements; discounts and rebates influence net prices.
- Overall, prices are expected to decline marginally (~5-10%) as market competition intensifies.
Long-term (2026-2030) Projections
- Pending biosimilar development and regulatory approvals, total treatment costs could decrease 20-30%.
- New indications or combination regimens targeting broader patient populations may stabilize or slightly increase pricing.
Factors Influencing Future Pricing
- Patent life expiration: US patent expiration estimated around 2030.
- Biosimilar entry: Potential for biosimilar HER2-targeted therapies, reducing prices by 20-40%.
- Payer negotiations: Increased formulary restrictions and value-based contracts.
Regulatory and Policy Environment
- Patent protections will likely extend until 2030.
- The FDA supports biosimilar development, with multiple biosimilars for HER2 therapy in development or approval stages.
- Health authorities emphasize cost-effectiveness, impacting reimbursement pathways and pricing.
Investment Implications
- Companies advancing biosimilars or novel HER2-targeted drugs could pressure prices downward.
- Market expansion into early-stage breast cancer or other HER2-positive cancers may increase total sales.
- Strategic collaborations and outcomes-focused reimbursement models will influence revenue streams.
Key Takeaways
- NDC 42291-0455 (Tucatinib) operates in a growing but competitive market segment with high unmet need in brain metastases.
- The drug’s current price points around $9,500 per month are expected to decline due to biosimilar competition and payer pressure.
- Market expansion into broader indications and combination therapies could sustain or increase revenue.
- Patent expiration around 2030 invites biosimilar competition, potentially decreasing prices by up to 40%.
- Pricing and reimbursement dynamics will evolve in response to policy shifts towards value-based care.
FAQs
1. How does Tucatinib compare to other HER2-targeted therapies in price?
Tucatinib’s monthly cost (~$9,500) is comparable to newer targeted therapies but higher than older agents like trastuzumab ($3,000 per dose).
2. When might biosimilars for HER2 therapies enter the U.S. market?
Biosimilars for trastuzumab have been approved since 2018; additional biosimilars for HER2-targeted agents are expected from 2025 onward, depending on regulatory approval and patent status.
3. What factors could accelerate or delay the market penetration of Tucatinib?
Factors include clinical adoption rates, reimbursement policies, new trial data demonstrating superiority or additional indications, and patent litigation outcomes.
4. How might changes in healthcare policy influence Tucatinib’s pricing?
Value-based payment models and cost-effectiveness assessments could lead to price negotiations, discounts, or formulary restrictions.
5. What are the key risks for investors interested in Tucatinib’s market?
Patent expiration around 2030, emergence of biosimilars, changing clinical guidelines, and competitive innovations pose significant risks.
Sources
[1] Food and Drug Administration. (2020). FDA approves tucatinib for HER2-positive metastatic breast cancer. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-tucatinib-her2-positive-metastatic-breast-cancer
[2] MarketWatch. (2022). HER2-positive breast cancer market analysis. Retrieved from https://www.marketwatch.com
[3] IQVIA. (2022). Global Oncology Market Data. Retrieved from https://www.iqvia.com
[4] FDA. (2022). Biosimilar Development and Approval. Retrieved from https://www.fda.gov
[5] Bloomberg Industry Research. (2023). Pharmaceutical Licensing and Pricing Trends.
